BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
This article was originally published in The Pink Sheet Daily
Executive Summary
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.